NCT04325776 - A Study of AL2846 Versus Zoledronic Acid in Subjects With Advanced Non-Small Cell Lung Cancer With Bone Metastasis | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 24, 2020

Primary Completion Date

May 31, 2021

Study Completion Date

November 30, 2021

Conditions

Bone Metastatic Non-small Cell Lung Cancer

Interventions

DRUG

AL2846

AL2846 is a multi-target tyrosine kinase receptor inhibitor with obvious selective to c-met.

DRUG

Zoledronic Acid Injection

Zoledronic acid is a bisphosphonate drug that has a strong inhibition of bone resorption and a potential to promote bone formation, and can be used for bone metastasis caused by malignant tumors.

Trial Locations (8)

110044

RECRUITING

Shenyang Chest Hospital, Shenyang

121001

RECRUITING

Jinzhou Central Hospital, Jinzhou

130031

NOT_YET_RECRUITING

China-Japan Union Hospital Of Jilin University, Changchun

230000

RECRUITING

Anhui Chest Hospital, Hefei

310020

RECRUITING

Sir Run Run Shaw Hospital (SRRSH), Hangzhou

314001

NOT_YET_RECRUITING

The First Hospital of Jiaxing, Jiaxing

324000

RECRUITING

Quzhou People's Hospital, Quzhou

450008

RECRUITING

Henan Cancer Hospital, Zhengzhou